Tag: Data

Io Therapeutics, Inc., offered information from research of IRX4204, the corporate’s section II medical improvement stage, extremely selective third era RXR nuclear receptor agonist compound, supporting its potential use for prevention and remedy of regular aging-related neurodegeneration, Parkinson’s illness, and Alzheimer’s illness
Page 3 of 3 1 2 3

Categories